Access to Targeted Therapies for Solid Tumors in Türkiye
Author(s)
Karaomerlioglu I
Turkish Medicines and Medical Devices Agency, Ankara, 06, Turkey
OBJECTIVES:
Targeted therapies have emerged as crucial components in cancer treatment in recent decades, offering promising outcomes for patients. However, accessing these therapies remains challenging for patients in Türkiye. This study aims to assess the availability of targeted therapies for solid tumors in Türkiye, focusing on reimbursement status.METHODS:
We reviewed official publications from regulatory authorities, including the US Food and Drug Administration (FDA) and the Turkish Medicines and Medical Devices Agency, as well as the public payer, the Social Security Institution. Our analysis included protein kinase inhibitors, monoclonal antibodies, antibody drug conjugates, endocrine therapies, and other targeted therapies. These therapies were analyzed based on their approved indications and reimbursement status in Türkiye as of June 2023.RESULTS: The FDA has approved a total of 110 targeted therapies for solid tumors,
with lung cancer (29%) and breast cancer (22.72%) attaining the highest rates of approval. Currently, 62.72% of these therapies are accessible in Türkiye, with a reimbursement rate of 71.01%, which includes named patient programs. Notably, brain cancer and gastrointestinal stromal tumors have the highest reimbursement rates (100%) among the accessible therapeutics options. However, despite an 85.71% accessibility rate, there is presently no reimbursed targeted therapy available for bladder cancer. Additionally, most protein kinase inhibitors, with the exception of FGFR, NTRK, and Pi3K inhibitors, are covered for the treatment of non-small cell lung cancer (NSCLC), breast cancer, kidney cancer, skin cancer, liver cancer, or thyroid cancer. It is also important to note that only one PD-1/PD-L1 inhibitor is reimbursed, and its coverage is limited to skin cancer, kidney cancer, and NSCLC.CONCLUSIONS:
The current reimbursement for targeted therapies across various cancer types in Türkiye is inadequate. While the approval of targeted therapies is crucial in addressing unmet medical needs, it is equally important to ensure equitable access to these therapies through comprehensive reimbursement coverage.Conference/Value in Health Info
2023-11, ISPOR Europe 2023, Copenhagen, Denmark
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
HPR139
Topic
Health Policy & Regulatory
Topic Subcategory
Approval & Labeling, Reimbursement & Access Policy
Disease
Oncology, Personalized & Precision Medicine